4 results match your criteria: "National Institute of Biotechnology in Negev[Affiliation]"
PLoS One
November 2014
Department of Pharmaceutical Sciences, School of Pharmacy Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts, United States of America.
We report an all-in-one platform - ScanDrop - for the rapid and specific capture, detection, and identification of bacteria in drinking water. The ScanDrop platform integrates droplet microfluidics, a portable imaging system, and cloud-based control software and data storage. The cloud-based control software and data storage enables robotic image acquisition, remote image processing, and rapid data sharing.
View Article and Find Full Text PDFAm J Hum Genet
September 2007
Morris Kahn Laboratory of Human Genetics, National Institute of Biotechnology in Negev, Beer-Sheva, Israel.
Lethal congenital contractural syndrome type 2 (LCCS2) is an autosomal recessive neurogenic form of arthrogryposis that is associated with atrophy of the anterior horn of the spinal cord. We previously mapped LCCS2 to 6.4 Mb on chromosome 12q13 and have now narrowed the locus to 4.
View Article and Find Full Text PDFAm J Hum Genet
September 2007
Morris Kahn Laboratory of Human Genetics, National Institute of Biotechnology in Negev, Beer-Sheva, Israel.
Lethal congenital contractural syndrome (LCCS) is a severe form of arthrogryposis. To date, two autosomal recessive forms of the disease (LCCS and LCCS2) have been described and mapped to chromosomes 9q34 and 12q13, respectively. We now describe a third LCCS phenotype (LCCS3)--similar to LCCS2 yet without neurogenic bladder.
View Article and Find Full Text PDFExp Gerontol
October 2007
Department of Microbiology and Immunology and National Institute of Biotechnology in Negev, Faculty of Health Sciences, Ben-Gurion University of Negev, PO Box 653, Beer-Sheva 84105, Israel.
Alzheimer's disease (AD) is an age-related progressive neurodegenerative disorder characterized by memory loss and severe cognitive decline. The etiology of the disease has not been explored, although a significant body of evidence suggests that neuronal dysfunction is caused by hyperphosphorylation and intracellular accumulation of the Tau protein, extracellular accumulation of the amyloid beta-peptide (Abeta), and the associated chronic activation of glial cells. Clearance of toxic Abeta, apoptotic cells and debris from the brain together with induction of neuronal repair mechanisms may all take place partially throughout the progression of AD, but therapeutic approaches based on knowledge of these processes have been unsuccessfully developed.
View Article and Find Full Text PDF